Correction: Trials 25, 58 (2024)
https://doi.org/10.1186/s13063-023-07834-8
Following publication of the original article [1], we have been notified that a correction is needed on page 3, paragraph 2 as shown below:
Original statement: “Additionally, CAM2029 administration can be undertaken by the patient or carer themselves using a pre-filled pen, whereas administration of both octreotide LAR and lanreotide ATG requires medical assistance”.
Corrected statement: • Corrected statement: “Additionally, CAM2029 administration can be undertaken by the patient or carer themselves using a pre-filled pen, whereas administration of both octreotide LAR and lanreotide ATG requires medical assistance; administration of lanreotide ATG also requires medical assistance in the USA, while in some regions such as the EU, a healthcare professional can decide that patients on a stable dose may self-administer or have lanreotide ATG administered by a trained person after appropriate training” – the relevant references are:
Lanreotide ATG:
US FDA label – https://www.accessdata.fda.gov/spl/data/3cbf9cb7-cf01-4062-9e57-43e0f1c267a1/3cbf9cb7-cf01-4062-9e57-43e0f1c267a1.xml
Octreotide LAR:
US FDA label – https://www.accessdata.fda.gov/spl/data/09e3ff5f-554a-4922-9478-d87d52e842d0/09e3ff5f-554a-4922-9478-d87d52e842d0.xml
The original article has been corrected.
Reference
Singh S, et al. Methodology of the SORENTO clinical trial: a prospective, randomised, active-controlled phase 3 trial assessing the efficacy and safety of high exposure octreotide subcutaneous depot (CAM2029) in patients with GEP-NET. Trials. 2024;25:58. https://doi.org/10.1186/s13063-023-07834-8.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
About this article
Cite this article
Singh, S., Ferone, D., Capdevila, J. et al. Correction: Methodology of the SORENTO clinical trial: a prospective, randomised, active-controlled phase 3 trial assessing the efficacy and safety of high exposure octreotide subcutaneous depot (CAM2029) in patients with GEP-NET. Trials 25, 297 (2024). https://doi.org/10.1186/s13063-024-08146-1
Published:
DOI: https://doi.org/10.1186/s13063-024-08146-1